SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition

Cancer Cell

Volumn 27, Issue 5, 2015, Pages 617-630

  Kim, Eunhee ^a   Ilagan, Janine O ^b   Liang, Yang ^c   Daubner, Gerrit M ^d   Lee, Stanley C W ^a   Ramakrishnan, Aravind ^b,e   Li, Yue ^f   Chung, Young Rock ^a   Micol, Jean Baptiste ^a   Murphy, Michele E ^b   Cho, Hana ^a   Kim, Min Kyung ^a   Zebari, Ahmad S ^b   Aumann, Shlomzion ^a   Park, Christopher Y ^a   Buonamici, Silvia ^g   Smith, Peter G ^g   Deeg, H Joachim ^b,e   Lobry, Camille ^h,i   Aifantis, Iannis ^j   Modis, Yorgo ^f,k   Allain, Frederic H T ^d   Halene, Stephanie ^c   Bradley, Robert K ^b   Abdel Wahab, Omar ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c YALE CANCER CENTER   (United States)

^d ETH ZURICH   (Switzerland)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f YALE UNIVERSITY   (United States)

^g EISAI INC   (United States)

^h INSERM   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; RNA; SERINE ARGININE RICH SPLICING FACTOR 2; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; EZH2 PROTEIN, MOUSE; NUCLEAR PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; RIBONUCLEOPROTEIN; SFRS2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; EXON; GENE MUTATION; HEMATOPOIESIS; HUMAN; IN VIVO STUDY; MOUSE; MUTANT; MYELODYSPLASTIC SYNDROME; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; PHENOTYPE; PRIORITY JOURNAL; RNA BINDING; SEQUENCE ANALYSIS; ANIMAL; GENE EXPRESSION; GENETICS; METABOLISM; MUTANT MOUSE STRAIN; MUTATION; PROTEIN DEGRADATION; RNA SPLICING;

ANIMALS; EXONS; GENE EXPRESSION; MICE; MICE, MUTANT STRAINS; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; POLYCOMB REPRESSIVE COMPLEX 2; PROTEOLYSIS; RIBONUCLEOPROTEINS; RNA SPLICING;

EID: 84929162813     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.04.006     Document Type: Article

References (32)

1. Bejar R., Stevenson K.E., Caughey B.A., Abdel-Wahab O., Steensma D.P., Galili N., Raza A., Kantarjian H., Levine R.L., Neuberg D., et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J. Clin. Oncol. 2012, 30:3376-3382.
2. Brooks A.N., Choi P.S., de Waal L., Sharifnia T., Imielinski M., Saksena G., Pedamallu C.S., Sivachenko A., Rosenberg M., Chmielecki J., et al. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS ONE 2014, 9:e87361.
3. Daubner G.M., Cléry A., Jayne S., Stevenin J., Allain F.H. A syn-anti conformational difference allows SRSF2 to recognize guanines and cytosines equally well. EMBO J. 2012, 31:162-174.
4. Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C., Jones A.V., Waghorn K., Zoi K., Ross F.M., Reiter A., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 2010, 42:722-726.
5. Graubert T.A., Shen D., Ding L., Okeyo-Owuor T., Lunn C.L., Shao J., Krysiak K., Harris C.C., Koboldt D.C., Larson D.E., et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat. Genet. 2012, 44:53-57.
6. Graveley B.R., Maniatis T. Arginine/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing. Mol. Cell 1998, 1:765-771.
7. Haferlach T., Nagata Y., Grossmann V., Okuno Y., Bacher U., Nagae G., Schnittger S., Sanada M., Kon A., Alpermann T., et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014, 28:241-247.
8. Hubert C.G., Bradley R.K., Ding Y., Toledo C.M., Herman J., Skutt-Kakaria K., Girard E.J., Davison J., Berndt J., Corrin P., et al. Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes Dev. 2013, 27:1032-1045.
9. Ilagan J.O., Ramakrishnan A., Hayes B., Murphy M.E., Zebari A.S., Bradley P., Bradley R.K. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2015, 25:14-26.
10. Kühn R., Schwenk F., Aguet M., Rajewsky K. Inducible gene targeting in mice. Science 1995, 269:1427-1429.
11. Lareau L.F., Inada M., Green R.E., Wengrod J.C., Brenner S.E. Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. Nature 2007, 446:926-929.
12. Liu H.X., Chew S.L., Cartegni L., Zhang M.Q., Krainer A.R. Exonic splicing enhancer motif recognized by human SC35 under splicing conditions. Mol. Cell. Biol. 2000, 20:1063-1071.
13. Moran-Crusio K., Reavie L., Shih A., Abdel-Wahab O., Ndiaye-Lobry D., Lobry C., Figueroa M.E., Vasanthakumar A., Patel J., Zhao X., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20:11-24.
14. Muto T., Sashida G., Oshima M., Wendt G.R., Mochizuki-Kashio M., Nagata Y., Sanada M., Miyagi S., Saraya A., Kamio A., et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J. Exp. Med. 2013, 210:2627-2639.
15. Ni J.Z., Grate L., Donohue J.P., Preston C., Nobida N., O'Brien G., Shiue L., Clark T.A., Blume J.E., Ares M. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. Genes Dev. 2007, 21:708-718.
16. Nikoloski G., Langemeijer S.M., Kuiper R.P., Knops R., Massop M., Tönnissen E.R., van der Heijden A., Scheele T.N., Vandenberghe P., de Witte T., et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 2010, 42:665-667.
17. Oguro H., Ding L., Morrison S.J. SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors. Cell Stem Cell 2013, 13:102-116.
18. Papaemmanuil E., Cazzola M., Boultwood J., Malcovati L., Vyas P., Bowen D., Pellagatti A., Wainscoat J.S., Hellstrom-Lindberg E., Gambacorti-Passerini C., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 2011, 365:1384-1395. Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium.
19. Papaemmanuil E., Gerstung M., Malcovati L., Tauro S., Gundem G., Van Loo P., Yoon C.J., Ellis P., Wedge D.C., Pellagatti A., et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013, 122:3616-3627. Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium, quiz 3699.
20. Pronk C.J., Rossi D.J., Månsson R., Attema J.L., Norddahl G.L., Chan C.K., Sigvardsson M., Weissman I.L., Bryder D. Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. Cell Stem Cell 2007, 1:428-442.
21. Przychodzen B., Jerez A., Guinta K., Sekeres M.A., Padgett R., Maciejewski J.P., Makishima H. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood 2013, 122:999-1006.
22. Quesada V., Conde L., Villamor N., Ordóñez G.R., Jares P., Bassaganyas L., Ramsay A.J., Beà S., Pinyol M., Martínez-Trillos A., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 2012, 44:47-52.
23. Schaal T.D., Maniatis T. Multiple distinct splicing enhancers in the protein-coding sequences of a constitutively spliced pre-mRNA. Mol. Cell. Biol. 1999, 19:261-273.
24. Siepel A., Bejerano G., Pedersen J.S., Hinrichs A.S., Hou M., Rosenbloom K., Clawson H., Spieth J., Hillier L.W., Richards S., et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005, 15:1034-1050.
25. 't Hoen P.A., Hirsch M., de Meijer E.J., de Menezes R.X., van Ommen G.J., den Dunnen J.T. mRNA degradation controls differentiation state-dependent differences in transcript and splice variant abundance. Nucleic Acids Res. 2011, 39:556-566.
26. Vannucchi A.M., Lasho T.L., Guglielmelli P., Biamonte F., Pardanani A., Pereira A., Finke C., Score J., Gangat N., Mannarelli C., et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013, 27:1861-1869.
27. Wagenmakers E.J., Lodewyckx T., Kuriyal H., Grasman R. Bayesian hypothesis testing for psychologists: a tutorial on the Savage-Dickey method. Cognit. Psychol. 2010, 60:158-189.
28. Wang H.Y., Xu X., Ding J.H., Bermingham J.R., Fu X.D. SC35 plays a role in T cell development and alternative splicing of CD45. Mol. Cell 2001, 7:331-342.
29. Wang L., Lawrence M.S., Wan Y., Stojanov P., Sougnez C., Stevenson K., Werner L., Sivachenko A., DeLuca D.S., Zhang L., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 2011, 365:2497-2506.
30. Yoshida K., Sanada M., Shiraishi Y., Nowak D., Nagata Y., Yamamoto R., Sato Y., Sato-Otsubo A., Kon A., Nagasaki M., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
31. Zahler A.M., Damgaard C.K., Kjems J., Caputi M. SC35 and heterogeneous nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing. J. Biol. Chem. 2004, 279:10077-10084.
32. Zhang S.J., Rampal R., Manshouri T., Patel J., Mensah N., Kayserian A., Hricik T., Heguy A., Hedvat C., Gönen M., et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 2012, 119:4480-4485.